Sponsored

Alexey Danilov, MD, PhD, Discusses the Use of Acalabrutinib for the Treatment of CLL, SLL, and MCL

 

In this video, Dr Danilov, Oregon Health & Science University, Portland, Oregon, discusses the use of acalabrutinib (Calquence; AstraZeneca) as a treatment option for patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).

Stay in the know.
OncNet Newsletter